Prof Mehanna interview with eCancer Conferences
6 December 2018
At this years ESMO conference in Munich, Professor Mehanna talked to eCancer about the results of the De-ESCALaTE study in which he reported that patients with HPV-positive oropharynx cancer should receive chemoradiotherapy rather than cetuximab with radiotherapy. You can see the interview here.
